Independent. Sources linked. No ad trackers.
Independent. Sources linked. Refreshed daily.

Your source for the latest in metronomic cancer therapy.

New research, clinical trials, and expert talks on low-dose, continuous chemotherapy, for people and for pets. Pulled from PubMed and ClinicalTrials.gov every day, with every source linked.

Every source linked Negative trials included No ad trackers
A doctor and an older man in conversation at a desk, both relaxed
Refreshed daily from PubMed and ClinicalTrials.gov. Last refresh: Nov 15, 2026
2000
The year the approach was first described
3
Phase 3 results from 2025 and 2026, summarized below
1,509
Publications indexed from PubMed
65
Trials recruiting or starting soon
Who the hub is for

Written for the person reading it

A woman and her father reading a tablet together at a kitchen table

Patients and caregivers

Plain-language answers and a printable list of questions to bring to your oncologist.

Updated daily
A pharmacist and a physician reviewing a tablet together in a clinic corridor

Clinicians

New trial publications, phase 3 results, and open studies, each linked to its original source.

Updated daily
A golden retriever sitting between its owner and a veterinarian

Pet owners

What low-dose chemotherapy means for dogs and cats, and what to ask a veterinary oncologist.

Updated daily
A hand marking a calendar beside a weekly pill organizer
Start here

What metronomic therapy is

Small doses of chemotherapy on a frequent, regular schedule with no long breaks, instead of the largest tolerable dose every few weeks.

The name comes from the steady tick of a metronome. The drugs most often studied are taken by mouth. The approach has been studied since 2000.

Researchers propose three main ways it may work: slowing the growth of tumor blood vessels, changing how the immune system responds, and acting on cancer cells directly. The best schedules, and which patients benefit most, are still being studied.

Compiled from the published sources cited. Not yet medically reviewed.
Recent milestones

What recent phase 3 trials found

Positive and negative results get the same space. Each result applies only to the cancer type and patient group named.

AStrong evidence Survival benefit reported

MECCA

Breast cancer: HR positive, HER2 negative, metastatic

263 patients in China. Metronomic capecitabine plus an aromatase inhibitor, compared with an aromatase inhibitor alone. Overall survival favored the combination (hazard ratio 0.58). More patients stopped treatment because of side effects in the combination group (16.7% versus 5.5%).

Journal of Clinical Oncology, 2025. Read the 2026 commentary
AStrong evidence Survival benefit reported

TMC-I

Head and neck cancer: recurrent or metastatic, platinum sensitive

422 patients in India. A triple oral metronomic regimen plus ultra-low-dose nivolumab, compared with paclitaxel and carboplatin. One-year overall survival was 46% versus 23%. Presented as a conference abstract.

ASCO 2026, abstract LBA6007. Read the OncLive report
BModerate evidence No efficacy advantage

METROPHOLYS

Soft tissue sarcoma: patients age 70 and over

A randomized phase 3 trial that closed early with a small number of patients. Metronomic cyclophosphamide did not outperform doxorubicin on efficacy. Serious treatment-related side effects were less common with the metronomic schedule (9.5% versus 33.3%).

Summaries of published studies. Compiled from the sources cited. Not yet medically reviewed. Not medical advice.

Newest phase 3 publications

Automated listing from PubMed, updated daily. Last refresh: Nov 15, 2026. Titles appear as published. Not medically reviewed.

See all 21 phase 3 publications

In the hub

One place for a scattered field

The research lives in journals, trial registries, conference abstracts, and news sites. The hub pulls it together and refreshes from primary sources every day.

Evidence by cancer type

Breast, lung, head and neck, ovarian, sarcoma, and more. New studies and open trials for each one.

Updated daily

Evidence by drug

Cyclophosphamide, capecitabine, vinorelbine, methotrexate, and others. Studies and trials for each drug.

Updated daily

Trial finder

From ClinicalTrials.gov. Filter by cancer type, country, phase, and recruiting status.

Refreshed daily

Research feed

New publications from PubMed, checked every day, each linked to the original. Full archive by year.

Updated daily

Questions for your oncologist

A printable discussion guide, so the next appointment covers what matters to you.

Printable guide

Expert video library

Talks and conference interviews with oncology researchers, from established medical publishers.

Selected talks
Common questions

Short answers first

Is metronomic therapy still chemotherapy?

Yes. It uses chemotherapy drugs. What changes is the schedule: smaller doses given frequently, with no long breaks. Background from review articles: Wu et al., 2024.

Is it used for dogs and cats?

Yes. Metronomic chemotherapy is used in veterinary oncology for dogs and cats, with drugs such as cyclophosphamide. Grade V, veterinary evidence, which applies to pets only. Source: review in Cancers, 2025.

Is it right for my situation?

That is a decision for you and your oncologist. This site explains what has been studied and in whom, and gives you questions to bring to your appointment.

Get the monthly brief

New research and trial news in metronomic therapy, about once a month. Email address only. Unsubscribe any time.

How we work

Built to be trusted

Independent

Not owned by a drug company, a clinic, or a trial recruiter. Funding is disclosed on the About page.

Sourced and graded

Every clinical statement links to its source. Study results carry an evidence grade.

Private by design

No advertising trackers. No sale of personal data. Ever.

Honest labels

Each page shows its true review status. We never claim a review that did not happen.

The evidence grades
AStrong evidence BModerate evidence CEarly evidence DLab research only EExpert opinion VVeterinary evidence